Latest in Intel’s next CEO faces ‘deadweight’ that won’t be easy to lift
Sort by
250 items
-
MLB rumors: Juan Soto nearing decision as bidding clears $600 million, Cardinals likely to trade Nolan Arenado
MLB's hot stove is heating up as Juan Soto gets closer to a choiceCBS Sports - 17h -
What's Next in the Legal Battle Over Elon Musk's $100 Billion Pay Deal
The Tesla CEO’s record-breaking compensation package has hit another roadblock, after a Delaware judge again rejected the deal.The Wall Street Journal - 1d -
Music sector workers to lose nearly a quarter of income to AI in next four years, global study finds
AI boom will enrich giant tech companies but creators’ rights and income will be drastically reduced unless policymakers intervene, report warns. Follow our Australia news live blog for latest ...The Guardian - 13h -
Political chaos in South Korea: what is martial law and what comes next after Yoon Suk Yeol’s U-turn?
Six hours after stunning the country by declaring martial law, Yoon reversed his decision and faced calls to step down. South Korea’s president, Yoon Suk Yeol, on Tuesday declared martial law, ...The Guardian - 20h -
BoE governor expects four UK rate cuts next year as inflation eases
Andrew Bailey welcomes better than expected fall in price growth in FT interviewFinancial Times - 8h -
These stocks aren’t likely to beat the S&P 500 next year — for this one reason
Difficult-to-short stocks often trade at artificially inflated, unsustainable prices.MarketWatch - 12m -
South Korea's short-lived martial law declaration rattled markets. Here's what's next for stocks
An extraordinary political drama in South Korea is likely to compound an already gloomy outlook for Asia's fourth-largest economy, analysts say.CNBC - 4h -
Patriots unveil plans for all-new practice facility next to Gillette Stadium, set for spring 2026 opening
The new complex is set to more than double the club's current spaceCBS Sports - 3h -
Eli Lilly's obesity drug beats rival in head-to-head trial — where Cramer sees shares going next
New trial data has cemented Club holding Eli Lilly's pole position in the highly competitive weight loss drug race.CNBC - 42m
